NVIDIA partners with Novo Nordisk to accelerate drug development using AI

Chip manufacturer NVIDIA announced on Wednesday a partnership with Novo Nordisk to accelerate the Danish pharmaceutical giant's efforts in drug development using artificial intelligence (AI). This collaboration is expected to support an agreement between Novo Nordisk and the Danish AI Innovation Center, which owns and operates Denmark's flagship AI supercomputer, Gefion. As part of the collaboration, the two companies will focus on developing customized AI models for Novo Nordisk researchers to use in the early stages of clinical development and running advanced simulation and physical AI technologies. Rory Kelleher, Senior Director of Business Development for Life Sciences at NVIDIA, stated, "By partnering with Novo Nordisk, we are advancing critical R&D applications with foundational tools that can fully leverage the potential of generative and agent-based AI to improve drug development." NVIDIA announced this news at the GTC event held in Paris, France, where the company also unveiled several key European partners